3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
3
Completed
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
3
Ovarian Neoplasms
2
Medulloblastoma
2
Lymphoma, B-Cell
2
Solid Tumor
1
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Pinealoma
1
Ovarian Germ Cell Cancer
1
Neuroectodermal Tumors, Primitive
1
Nervous System Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Glioma
1
Ganglioneuroblastoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
etoposide phosphate
×
Clear all
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled